Hearing Loss, Sensorineural
Conditions
Keywords
Hearing loss, Intratympanic Injection
Brief summary
This single-blind, placebo-controlled trial will be conducted to evaluate the safety of FX-345 administered as a single intratympanic injection in adults with acquired sensorineural hearing loss. The primary objectives are to assess the local safety, systemic safety, and pharmacokinetic (PK) profile to determine systemic exposure.
Detailed description
This study will enroll two cohorts. Cohort 1 (n=9) will be enrolled first to rapidly assess safety and drug exposure. After the sponsor completes an unblinded safety review, Cohort 2 (n=27) will be enrolled to continue safety evaluation of FX-345.
Interventions
DRUGFX-345
Single intratympanic injection of FX-345
DRUGPlacebo
Single intratympanic injection of placebo
Sponsors
Frequency Therapeutics
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 67 Years
Healthy volunteers
No
Inclusion criteria
* Adult aged 18-67 years (inclusive) * Documented medical history consistent with acquired, adult onset, sensorineural hearing loss * At the Screening, Lead-in (Visit 2) and Treatment (Day 1) Visits, a pure tone average of 40- 80 dBHL at 500Hz, 1000Hz, 2000Hz, and 4000Hz in the potential study ear to be injected * Female participants must not be pregnant, breastfeeding, or lactating. Women of child-bearing potential must agree to use a highly effective contraceptive method and must have a negative urine pregnancy test. * Male participants must refrain from donating sperm and agree to be either abstinent or use a barrier method of contraception
Exclusion criteria
* Randomization in a FX-322 (laduviglusib and sodium valproate) clinical trial * Perforation of tympanic membrane or other tympanic membrane disorders that would interfere with the delivery and safety assessment of an intratympanic medication or reasonably be suspected to affect tympanic membrane healing after injection in study ear. This includes a current tympanostomy tube. * Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10 dB at two or more contiguous octave frequencies in the study ear at the Screening, Lead-in (Visit 2) or Treatment (Day 1) Visits, based on the investigator's judgment. * Active chronic middle ear disease or a history of major middle ear surgery, as an adult, in the ear to be injected. * Within 3 months of screening visit any of the following: 1) an intratympanic injection in either ear 2) treatment with steroids 3) onset of sudden sensorineural hearing loss * Evidence of or previous diagnosis of traumatic brain injury, Meniere's disease, or genetic hearing loss * History of head or neck radiation, significant systemic autoimmune disease, and/or chronic, recurrent clinically significant vestibular symptoms * Exposure to another investigational drug within 28 days prior to screening visit
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Event(s) (TEAEs) | Baseline Through Day 90 | — |
| Cmax | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | Maximum (peak) observed plasma drug concentration of FX04 and FX00 in cohort 1 participants |
| AUClast | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | Area under the concentration-time curve of FX04 and FX00 in cohort 1 participants |
| CL/F | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | Apparent total body clearance of FX04 and FX00 in cohort 1 participants |
| Vss | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | Apparent volume of distribution at steady state of FX04 and FX00 in cohort 1 participants |
| t1/2 | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | Elimination half-life of FX04 and FX00 in cohort 1 participants |
| Tmax | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | Time to reach maximum (peak) plasma drug concentration of FX04 and FX00 in cohort 1 participants |
| Elimination rate constant | Data points taken pre-dose and 0.5, 1, 2, 4, 6, 24 hours post-dose | The rate at which FX04 and FX00 is removed from the human system in cohort 1 participants |
Countries
United States
Outcome results
None listed